Rebecca S Kristeleit

Apr 23, 2024 | onclive.com | Rebecca S Kristeleit

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, consultant medical oncologist, clinical senior lecturer, Department of Oncology, University College-London Cancer Institute, discusses the phase 3 ATHENA-MONO trial (NCT03522246) in newly diagnosed patients with advanced ovarian cancer, highlighting the clinical implications of these long-term findings.

Apr 17, 2024 | onclive.com | Rebecca S Kristeleit

April 17, 2024Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the phase 3 ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.

Apr 5, 2024 | onclive.com | Rebecca S Kristeleit

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, consultant medical oncologist and clinical senior lecturer, University College-London Cancer Institute, discusses key efficacy outcomes derived from 3-year follow-up data from newly diagnosed patients with advanced ovarian cancer treated in the phase 3 ATHENA-MONO trial (NCT01968213).

Jul 25, 2023 | nature.com | James B. Spicer |Udai Banerji |Rebecca S Kristeleit |Rowan Miller |Christopher J Corrigan |Silvana Canevari | +8 more

AbstractAll antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose escalation trial (NCT02546921) with the primary objective of exploring the safety and tolerability of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumours expressing the relevant antigen, folate receptor-alpha.